Gilead stops 3 filgotinib trials pending FDA feedback on faltering JAK1 inhibitor

Gilead has paused enrollment in clinical trials of filgotinib in three indications pending feedback from the FDA. The cessation of enrollment follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.